- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04356846
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
April 28, 2023 updated by: The First Affiliated Hospital with Nanjing Medical University
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Oral BCL-2 Inhibitor LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
This study is a multi-center, open-label, single-arm phase I clinical study of LP-108.
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL, arm A) and other B cell non-Hodgkin's lymphoma (NHL, Arm B).
Each arm has a dose escalation phase (phase Ia) and expansion phase (phase Ib).
During the dose escalation phase, the primary objectives are to define dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and to explore a recommended phase II dose.
Dose escalation is based on the classic "3 + 3" design, while accelerated titration is applied to the initial lower doses.
After the RP2Ds are determined, additional patients will be enrolled in the expansion phase to further evaluation the safety, PK and preliminary efficacy of LP-108, each therapy can enroll 12-20 subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
74
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Per 2017 revised WHO lymphoma classification criteria, subject must have either:
- (Arm A) Diagnosed with relapsed or refractory CLL and require treatment in the opinion of the Investigator.
- (Arm B) Diagnosed with relapsed or refractory non-Hodgkin's lymphoma associated with B-cell proliferation (such as SLL \ MCL \ FL \ MZL \ DLBCL \ WM, etc.) in need of treatment.
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1.
- Subject must have adequate bone marrow function independent of growth factor support per local laboratory reference range at Screening.
- Subject must have adequate coagulation, renal, and hepatic function, per local laboratory reference range at Screening.
- All acute toxicity from previous anti-tumor treatment or surgery has been alleviated to NCI CTCAE 5.0 ≤ Grade 1.
- All enrolled patients should take medically approved contraceptives during the entire treatment period and within 90 days after the end of treatment.
- Subjects must be willing to provide valid diagnostic evidence or accept bone marrow biopsy before treatment and accept bone marrow biopsy after treatment start.
- Patients with NHL who have undergone autologous stem cell transplantation must complete the transplantation operation for more than 6 months when enrolled, and have sufficient bone marrow function without relying on growth factor stimulation.
- Volunteer and sign informed consent, willing to follow trial protocol.
Exclusion Criteria:
- According to the 2017 revised WHO Lymphoma Classification Criteria, patients diagnosed with the following diseases: Burkitt lymphoma or Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, and post-transplant lymphoproliferative disease(PTLD) .
- Previously received other BCL-2 protein family inhibitors.
- CLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant.
Subjects who have received the following treatments within 4 weeks or 5 half-lives before the first dose of LP-108:
- Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and / or immunotherapy;
- Any investigational treatment;
- Patients who have undergone major surgery, severe trauma or radiotherapy.
Subjects who have received the following treatments within 2 weeks before the first dose of LP-108:
- Steroids or traditional herbal medicine for antitumor purposes;
- Strong and moderate CYP3A4/5 inhibitors and inducers, P-gp inhibitors and CYP2C8 sensitive substrates;
- All drugs that may cause QTc interval prolongation or torsional tachycardia.
- Have had malignancies other than the indications targeted in this study in the past three years, except for basal cell carcinoma of the skin and cervical carcinoma in situ treated radically.
- Any serious and / or uncontrolled systemic disease.
- Poor cardiovascular function, in line with New York Heart Association (NYHA) cardiac function classification ≥ 2 or QTcF greater than 480ms on ≥ 3 independent ECG.
Disease states where clinical manifestations may be difficult to control, including
- HIV, HBV, HCV, syphilis positive or active bacterial and fungal infections;
- Disease affects the central nervous system with obvious symptoms;
- Autoimmune hemolytic anemia or Idiopathic thrombocytopenic purpura.
- Any gastrointestinal conditions that may severely affect the study drug absorption or pharmacokinetic parameters.
- Patients who were unable to discontinue taking CYP2C8 substrate repaglinide to control type 2 diabetes during the study.
- Subjects who cannot tolerate urine collection, venipuncture, lymph node biopsy, and bone marrow aspiration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: R/R CLL
Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
|
Taken orally within 30 minutes after a meal at the designated dose, once daily.
|
Experimental: R/R NHL
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
|
Taken orally within 30 minutes after a meal at the designated dose, once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RP2D), and lead-in period regimen
Time Frame: Lead-in period (0-4 weeks) plus 3 weeks of study drug administration at the designated cohort dose.
|
Protocol-defined events, which can not be attributed by the investigator to a clearly identifiable cause such as tumor progression, underlying illness, concurrent illness, or concomitant medication, will be considered a DLT.
Dose limiting toxicities of tumor lysis syndrome observed during the lead-in period will be attributed to the lead-in period.
|
Lead-in period (0-4 weeks) plus 3 weeks of study drug administration at the designated cohort dose.
|
Number of subjects with adverse events and its frequency
Time Frame: From first dose of study drug administration until 30 days after study drug discontinue.
|
Safety Proflie
|
From first dose of study drug administration until 30 days after study drug discontinue.
|
Determination of plasma peak concentration (Cmax) of LP-108
Time Frame: Up to Week 37 for LP-108.
|
Blood and urine samples for pharmacokinetic analysis of LP-108 will be collected at designated time points.
|
Up to Week 37 for LP-108.
|
Determination of Area Under the Curve (AUC) of LP-108
Time Frame: Up to Week 37 for LP-108.
|
Blood and urine samples for pharmacokinetic analysis of LP-108 will be collected at designated time points.
|
Up to Week 37 for LP-108.
|
Food Effect - Cmax
Time Frame: Pharmacokinetic (PK) parameter Cmax (maximum plasma concentration of LP-108) between each diet (LP-108 under fasting versus fed conditions),up to week 8 for LP-108.
|
Blood samples for food effect pharmacokinetic analysis of LP-108 will be collected at designated time points
|
Pharmacokinetic (PK) parameter Cmax (maximum plasma concentration of LP-108) between each diet (LP-108 under fasting versus fed conditions),up to week 8 for LP-108.
|
Food Effect - AUC
Time Frame: Pharmacokinetic (PK) parameter AUC (area under the curve of LP-108) between each diet (LP-108 under fasting versus fed conditions),up to week 8 for LP-108.
|
Blood samples for food effect pharmacokinetic analysis of LP-108 will be collected at designated time points
|
Pharmacokinetic (PK) parameter AUC (area under the curve of LP-108) between each diet (LP-108 under fasting versus fed conditions),up to week 8 for LP-108.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary efficacy assessment
Time Frame: Designated dose starting week for clinical disease progression and tumor response; and every 4-12 weeks thereafter until the date of first documented progression or date of death from any cause, whichever came first,.assessed up to 24 months.
|
Tumor response or clinical disease progression
|
Designated dose starting week for clinical disease progression and tumor response; and every 4-12 weeks thereafter until the date of first documented progression or date of death from any cause, whichever came first,.assessed up to 24 months.
|
Minimal residual disease (MRD)
Time Frame: At least 2 months after the CR, CRi criteria for tumor response are first met. Measured up to 24 months after the last subject has enrolled in the study.
|
MRD assessed in the peripheral blood and/or bone marrow (BM) either by four color flow cytometry or NGS, will be measured in CLL subjects achieving CR/CRi.
|
At least 2 months after the CR, CRi criteria for tumor response are first met. Measured up to 24 months after the last subject has enrolled in the study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2020
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
April 10, 2020
First Submitted That Met QC Criteria
April 20, 2020
First Posted (Actual)
April 22, 2020
Study Record Updates
Last Update Posted (Actual)
May 1, 2023
Last Update Submitted That Met QC Criteria
April 28, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LP-108-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on LP-108 tablet
-
Newave Pharmaceutical IncRecruitingRefractory Acute Lymphoblastic Leukemia | Relapse | CMML | Relapsed Adult AML | AML/MDS | Relapse LeukemiaUnited States, Spain
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
Guangzhou Lupeng Pharmaceutical Company LTD.Recruiting
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
Guangzhou Lupeng Pharmaceutical Company LTD.Recruiting
-
Guangzhou Lupeng Pharmaceutical Company LTD.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaChina
-
Charleston Laboratories, IncCompleted
-
Dow Pharmaceutical SciencesCompleted
-
University of California, San FranciscoCompletedProgressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17United States
-
SRI InternationalTaiho Pharmaceutical Co., Ltd.CompletedBreast CancerUnited States